MIM
CAPR icon

MetLife Investment Management’s Capricor Therapeutics CAPR Stock Holding History

MetLife Investment Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$705K Buy
23,195
+1,219
+6% +$32.5K ﹤0.01% 1582
2025
Q4 		$634K Buy
21,976
+7,740
+54% +$101K ﹤0.01% 1680
2025
Q3 		$103K Sell
14,236
-8,006
-36% -$58.9K ﹤0.01% 2641
2025
Q2 		$221K Hold
22,242
– – ﹤0.01% 2139
2025
Q1 		$211K Sell
22,242
-444
-2% -$6.16K ﹤0.01% 2171
2024
Q4 		$313K Buy
+22,686
New +$398K ﹤0.01% 2048

Other funds holding CAPR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

MetLife Investment Management's CAPR Position: Q1 2026 in Review

MetLife Investment Management increased its Capricor Therapeutics (CAPR) stake by 5.5% in Q1 2026, buying an estimated $32.5K and bringing the position to 23,195 shares worth $705K. The position accounts for ﹤0.01% of the portfolio, ranked #1582.

MetLife Investment Management first reported a position in CAPR in Q4 2024 and has held it in 6 quarters since. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

  • MetLife Investment Management held 23,195 shares of Capricor Therapeutics worth $705K as of Q1 2026.
  • MetLife Investment Management bought 1,219 Capricor Therapeutics shares in Q1 2026, an estimated $32.5K.
  • Capricor Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1582 holding.
  • MetLife Investment Management first reported a position in Capricor Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.